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ABSTRACT
Hepatocellular carcinoma (HCC) is a deadly malignancy characterized at the epigenetic level by global DNA
hypomethylation and focal hypermethylation on the promoter of tumor suppressor genes. In most cases it
develops on a background of liver steatohepatitis, ﬁbrosis, and cirrhosis. Guadecitabine (SGI-110) is a second-
generation hypomethylating agent, which inhibits DNA methyltransferases. Guadecitabine is formulated as a
dinucleotide of decitabine and deoxyguanosine that is resistant to cytidine deaminase (CDA) degradation and
results in prolonged in vivo exposure to decitabine following small volume subcutaneous administration of
guadecitabine. Here we found that guadecitabine is an effective demethylating agent and is able to prevent HCC
progression in pre-clinical models. In a xenograft HCC HepG2model, guadecitabine impeded tumor growth and
inhibited angiogenesis, while it could not prevent liver ﬁbrosis and inﬂammation in a mouse model of
steatohepatitis. Demethylating efﬁcacy of guadecitabine on LINE-1 elements was found to be the highest 8 d
post-infusion in blood samples of mice. Analysis of a panel of human HCC vs. normal tissue revealed a signature
of hypermethylated tumor suppressor genes (CDKN1A, CDKN2A, DLEC1, E2F1, GSTP1, OPCML, E2F1, RASSF1,
RUNX3, and SOCS1) as detected by methylation-speciﬁc PCR. A pronounced demethylating effect of
guadecitabine was obtained also in the promoters of a subset of tumor suppressors genes (CDKN2A, DLEC1, and
RUNX3) in HepG2 and Huh-7 HCC cells. Finally, we analyzed the role of macroH2A1, a variant of histone H2A, an
oncogene upregulated in human cirrhosis/HCC that synergizes with DNA methylation in suppressing tumor
suppressor genes, and it prevents the inhibition of cell growth triggered by decitabine in HCC cells.
Guadecitabine, in contrast to decitabine, blocked growth in HCC cells overexpressing macroH2A1 histones and
with high CDA levels, despite being unable to fully demethylate CDKN2A, RUNX3, and DLEC1 promoters altered
by macroH2A1. Collectively, our ﬁndings in human and mice models reveal novel epigenetic anti-HCC effects of
guadecitabine, whichmight be effective speciﬁcally in advanced states of the disease.
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Introduction
Hepatocellular carcinoma (HCC) is the second leading cause of
cancer-related death and the sixth most frequently diagnosed
cancer worldwide. Prognosis is poor, as only 10 to 20% of
patients with HCC are eligible for surgery; without it, patients
are expected to survive less than 6 months.1 HCC is often trig-
gered, in an age-dependent manner, by viral infection, metabolic
syndrome, and non-alcoholic fatty liver disease (NAFLD), along
with the insurgence of cirrhosis.2 There is no clear understand-
ing of the epigenetic alterations in HCC or the potential role of
DNA methylation markers as prognostic biomarkers. Nonethe-
less, global DNA hypomethylation, accompanied by focal hyper-
methylation, is generally found in HCC compared to healthy
liver tissue.3-5 Histone variants provide continuous regulation of
nucleosome turnover across the entire lifespan of the organism
in vertebrates, and they are a primary cellular strategy to regulate
transcription and cellular metabolism.6 Speciﬁcally, the histone
H2A variant macroH2A1, comprising 2 alternatively spliced iso-
forms, macroH2A1.1 and macroH2A1.2, is a marker of human
HCC.7 MacroH2A1 isoforms have taken center stage in the plas-
ticity of stem cell differentiation and in the pathogenesis of many
cancers, providing an exciting, yet poorly understood, link to
metabolism and nutrients.8 Interestingly, macroH2A1 function
and DNA methylation are functionally linked: in human ﬁbro-
blasts, macroH2A1 deﬁciency combined with 5-aza-deoxycyti-
dine (5-aza-dC, decitabine) treatment activates tumor-
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suppressor genes (TSG) and inhibits cell proliferation.9 In the
presence of HCC-associated DNA hypomethylation, high levels
of macroH2A1 favor HCC progression through a distinct p38
MAPK/IL8-dependent mechanism that is accompanied by
escape from senescence.3 Hypomethylating agent decitabine
and its derivatives inhibit DNA methyltransferases proteins and
are mainly used for the treatment of myeloid malignancies, such
as myelodisplastic syndrome (MDS) and acute myeloid leuke-
mia (AML), although they also exert antitumor effects in vitro
by inducing senescence.10-14 Guadecitabine is a second-genera-
tion hypomethylating agent designed as a dinucleotide of decita-
bine and deoxyguanosine that is resistant to cytidine deaminase
(CDA) 15 and results in prolonged in vivo exposure to decitabine
following small volume subcutaneous administration of guade-
citabine. Safety and clinical activity in MDS and AML have been
shown in a phase 1 trial.16,17 CDA rapidly metabolizes decitabine
into inactive uridine counterparts, severely limiting exposure
time and oral bioavailability. High expression of CDA is a dis-
tinctive feature of poor-prognosis leukemias.18 In the liver, high
CDA expression provides a “sanctuary” for cancer cells from
decitabine treatment effects; this mechanism of resistance could
be reversed in murine models, without increasing toxicity, by
combining decitabine with an inhibitor of CDA,19 a strategy
now employed in ongoing clinical trials for myelodisplastic syn-
dromes.20,21 Preliminary evidence suggests that guadecitabine
synergizes with other chemotherapeutics (sorafenib, oxaliplatin)
in slowing downHCC cell growth in vitro13,14 and a phase 2 clin-
ical study evaluated guadecitabine single agent activity in
patients with HCC after progression on sorafenib.22 The aims of
this study were to investigate the efﬁcacy of guadecitabine in
pre-clinical HCC models and to unravel its interplay with mac-
roH2A1 oncogenes in regulating TSG promoter methylation
and cancer growth. To this purpose we used xenograft and
chemical/dietary mice models of liver diseases, macroH2A1-iso-
form speciﬁc transgenic HCC cell lines, and human liver tissues.
We found that guadecitabine administration to decitabine resis-
tant macroH2A1-overexpressing HCC cells and to HCC xeno-
graft mouse model was able to hamper cancer growth, while it
had not therapeutic effect on steatohepatitis.
Results
Guadecitabine (SGI-110) treatment inhibits HepG2 cell
growth and vascularization in immunodeﬁcient mice but
does not affect pre-neoplastic stages in a dietary NASH
model.
To investigate the in vivo antitumor efﬁcacy of guadecitabine,
xenograft studies were performed in athymic nude mice.13
Subcutaneous HCC xenografts from HepG2 cells were estab-
lished on the dorsal ﬂank of balb/c immunodeﬁcient mice,
and treated with guadecitabine until tumor size in the control/
untreated group reached 1400 mm3 (approximately 28 d post-
inoculation). Treatment was given in a 3-day cycle, where
guadecitabine (2 mg/kg) was given daily on Day 1–3. This
mode of administration was chosen because in this mouse
strain led to consistent LINE-1 demethylation in peripheral
blood mononuclear cells, indicative of drug systemic efﬁcacy,
which was greater 9 d than 16 d post-treatment (Fig. 1).
Xenografted mice were sacriﬁced and samples were collected
when tumor sizes reached 1400 mm3 in the vehicle (PBS-
injected) group, approximately 4 weeks post-inoculation.
Organ sections of liver, kidney, heart, lung, spleen, and pan-
creas did not reveal major histopathological changes (data not
shown). Tumor burden could be assessed only in 9 of the 14
mice of the guadecitabine group, whereas all 14 PBS-injected
mice developed tumors. Tumor size was variable both within
the PBS-injected and within the guadecitabine-injected groups
(Fig. 2A); no statistical difference in tumor size between the 2
experimental groups has been observed. However, a strikingly
different weight range distribution was found, as 71% (10 out
of 14) of the tumors of the PBS group compared to 33% (3
out of 9) of the tumors of the guadecitabine group were
heavier than 0.2 g (Fig. 2B). LINE-1 were found consistently
demethylated in HepG2-derived tumors from guadecitabine
treated animals compared to PBS-injected ones (Fig. S1A).
Moreover, analysis of a DNA methylation array of 22 human
tumor suppressor genes involved in HCC uncovered high
hypermethylation levels of DAB2IP, DLEC1, GSTP1, RASSF1,
RUNX3, and SOCS1 promoters in the HepG2-derived tumors
from PBS-injected animals; these promoters were signiﬁcantly
demethylated upon guadecitabine treatment (Fig. S1B). Gua-
decitabine thus suppressed the growth of tumors, as detected
at sacriﬁce, with therapeutic responsiveness detected at the
level of both global and focal DNA methylation. Isolectin B4
ﬂuorescent staining showed that the densities of the capillaries
in the HepG2 xenografts of control PBS-injected animals were
much higher compared to guadecitabine-injected animals
(Fig. 2C). Therefore, guadecitabine inhibits HCC growth and
angiogenesis in a xenograft model. Non-alcoholic fatty liver
disease (NAFLD), an accumulation of intra-hepatic triglycer-
ides, is the most common cause of chronic liver disease in
Western countries with up to one third of the population
affected. NAFLD include a spectrum of disturbances that
encompasses various degrees of liver damage ranging from
Figure 1. Relative changes in LINE-1 methylation levels in blood samples of balb/c
mice treated with guadecitabine. Two months old female female Balb/c nude
mice (BALB/cOlaHsd-Foxn1nu)balb/c Huh-7 tumor-bearing mice were injected s.c.
with 2 mg/kg of guadecitabine and LINE-1 demethylation levels in whole blood
[calculated as (methylation levels at day x – methylation levels at day 0)/(methyla-
tion levels day 0 100)] were assessed at 9 and at 16 d post guadecitabine adminis-
tration. Results for individual mice are shown. Six out of 8 mice (75%) show a
distinct relative LINE-1 demethylation.
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simple steatosis to non-alcoholic steatohepatitis (NASH).23
NASH is characterized by hepatocellular inﬂammation with
ﬁbrosis. Individuals with NASH are also at great risk of devel-
oping HCC. For this reason, here we used the STAM mouse,
a model of NASH progression resembling the disease in
humans.24 On the second day after birth, male mice were sub-
jected to a single subcutaneous injection of 200mg streptozo-
tocin. Four weeks after injection, mice were fed high fat diet
(60% energy from lard) ad libitum until sacriﬁce at 10 weeks.
Two experimental groups were considered, a control group
(n D 9) and a group injected SC with guadecitabine (2 mg/kg,
guadecitabine) (n D 8) at week 8 for 3 consecutive days. All
mice were sacriﬁced at week 10. These time points were cho-
sen because well characterized STAM mice develop NASH at
week 8 and ﬁbrosis, inﬂammation, and pre-neoplastic foci at
week 10–12 (data not shown and24,15). Guadecitabine admin-
istration led to »9% decrease in LINE-1 methylation levels in
the livers of STAM mice as compared to age-matched mice
fed a chow diet (controls); STAM mice, in turn, displayed
LINE-1 methylation levels similar to those of controls
(Fig. S2A). Surprisingly, despite unaltered LINE-1 methylation
levels when comparing diets, the livers of STAM mice exhib-
ited an increase in the maintenance DNA methyltransferase
protein, DNMT1, compared to control mice (Fig. S2B). Upon
administration of guadecitabine, DNMT1 protein levels
returned to basal (Fig. S2B). Guadecitabine did not affect
body weight (Fig. 3A) or the levels of circulating
transaminases ALT and AST (Fig. 3B and C), and did not
induce changes in plasma triglycerides (Fig. 3D). Immunopo-
sitivity for a-smooth muscle actin (aSMA), a marker of liver
ﬁbrosis, was observed in STAM mice, without tangible differ-
ences between control and guadecitabine-treated mice
(Fig. 3E). Moreover, glutamine synthetase positive foci were
found in the livers of STAM mice. Glutamine synthetase foci
represent putative preneoplastic and neoplastic lesions during
initial stages of hepatocarcinogenesis: no differences were
observed upon guadecitabine injections (Fig. 3F). We conclude
that although guadecitabine is not hepatotoxic and could be
effective in reducing tumor mass, it might not be effective in
alleviating inﬂammation and ﬁbrosis in the experimental
models used.
Human HCC methylation signature: effect of
guadecitabine
DNA methylation markers can be used as prognostic bio-
markers for HCC. A recent analysis of tumor tissue from 304
patients with HCC treated with surgical resection generated a
methylation-based prognostic signature that correlated with
predictors of poor outcome and prognostic capacity of survival.5
Patient derived xenografts (PDX), without in vitro manipula-
tion, mirror patient histopathological and genetic proﬁles and
are increasingly recognized to be predictive models for evaluat-
ing anti-cancer therapies. Here, we compared HCC PDX
Figure 2. Guadecitabine (Guad) prevents tumor growth in a HepG2 xenograft model. A. Pictures of explanted HepG2 tumors from PBS- and guadecitabine-injected
immunocompromised mice, next to a ruler. B. Tumor growth in balb/c mice inoculated with HepG2 cells. The control group (n D 14) was injected with PBS while the
experimental group (n D 14) was injected daily with 2 mg/kg guadecitabine from day 1 to 3 post-inoculation. Animals were sacriﬁced after 38 d, tumors were excised,
and tumor, and volume/weight were assessed by means of a caliper and a precision scale, respectively. C. Tumors as in A-B were processed for H&E staining or for immu-
noﬂuorescence with antibody against IsolectinB4 (IB4). For IF staining, nuclei were counterstained with DAPI.
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resistant to sorafenib (Nexavar), a tyrosine kinase inhibitor
approved for HCC therapy, to normal liver tissue from a healthy
donor for possible differences in their DNA methylation signa-
ture, using a DNA methylation array of 22 human tumor sup-
pressor genes involved in HCC (Fig. 4). Ten genes showed
methylation differences between healthy liver tissue and malig-
nant tissue: CDKN1A, CDKN2A, DLEC1, E2F1, GSTP1,
OPCML, E2F1, RASSF1, RUNX3, and SOCS1 (Fig. 4A). These
genes, whose promoter is unmethylated in normal liver tissue
and hypermethylated in HCC, might prove useful candidate
markers to further investigate if different DNA methylation lev-
els play a role in the sensitivity to chemotherapy in HCC.
Guadecitabine blocks the proliferation of decitabine-
resistant HCC cells
Histone variants macroH2A1.1 and macroH2A1.2 are strong
immunohistochemical markers of human HCC, as they are
foundmassively upregulated in malignant compared to cirrhotic
Figure 3. Guadecitabine (Guad) treatment does not inﬂuence liver ﬁbrosis and preneoplastic foci formation in a NASH mouse model (STAM). The experimental group of
mice was injected at week 8 with 2 mg/kg guadecitabine and sacriﬁced at week 10. A. Mice body weights were assessed daily after initial guadecitabine injection. B and
C. ALT and AST transaminases levels (U/L) measured in mice sera upon sacriﬁce. D. Plasma triglycerides (mg/dL) measured in mice sera upon sacriﬁce. E. Immunohisto-
chemical staining for aSMA in the livers of control vehicle-injected STAM mice (upper panel) or guadecitabine injected (lower panel). F. Immunohistochemical staining
for glutamine synthetase (GS) in the livers of control vehicle-injected STAM mice (upper panel) or guadecitabine injected (lower panel). n D 9 for untreated STAM mice;
n D 8 for guadecitabine-injected animals. Differences were not statistically signiﬁcant (ns).
Figure 4. HuPrime PDX HCC Sorafenib resistant tumor DNA was compared with normal liver tissue from a healthy donor for differences in their DNA methylation signa-
ture shown as HM: hypermethylated levels for each marker gene. Liver Cancer EpiTect Methyl II PCR Arrays were used to measure CpG island methylation of a panel of 22
tumor suppressor genes involved in HCC development and progression (CCND2, CDH1, CDKN1A, CDKN1B, CDKN2A, DLC1, DLEC1, E2F1, EP300, FHIT, GSTP1, MSH2, MSH3,
OPCML, SOCS1, E2F1, RASSF1, RELN, RUNX3, SFRP2, TNFRSF10D, WT1). Results for PDX are shown as the average of 8 individual sorafenib-resistant HCC models vs. methyla-
tion levels in healthy liver tissue.
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and mildly steatotic HCC (Fig. 5).3,7 Recently, we also demon-
strated that these histone variants confer resistance to decita-
bine-induced senescence and block in cell growth, highjacking
the senescence-associated secretory program in HCC cells.3 We
thus employed previously reported lentiviral-mediated stable
HepG2 and Huh-7 cell lines transgenic for green ﬂuorescent
protein (GFP), macroH2A1.1-GFP, or macroH2A1.2-GFP
(Fig. 6A and B)3 to study the functional differences between dec-
itabine and guadecitabine. As expected, macroH2A1.1-GFP and
macroH2A1.2-GFP transgene-bearing HepG2 and Huh-7 cells
displayed a signiﬁcant 2- to 3-fold increase in cell growth com-
pared with control GFP-expressing cells after 12 mM decitabine
treatment at 72 h, while there were no differences in the prolifer-
ation rate of untreated cells (Fig. 6C and D). In contrast to deci-
tabine, incubation with guadecitabine at lower doses of 1 mm
and 5 mM blocked HepG2 and Huh-7 cell proliferation at 72 h
to similar extent in all genotypes (Fig. 6C andD). The only struc-
tural difference between guadecitabine and decitabine is the
addition of a guanosine. Guadecitabine is resistant to inactiva-
tion by CDA,15 which is highly expressed in liver and gut, and is
Figure 5. Representative pictures of immunostainings for macroH2A1.1 (m1.1) and macroH2A1.2 (m1.2) in samples from patients diagnosed with hepatocellular carci-
noma (HCC), cirrhosis, and steatosis. Bar: 100 mM. All nuclei of tumor cells were positive for either m1.1 or m1.2. Positivity in hepatocytes of cirrhosis and steatosis was sig-
niﬁcantly lower.
Figure 6. Representative images of HepG2 (A) and Huh-7 cells (B) transgenic for GFP, macroH2A1.1-GFP (macroH2A1.1) and macroH2A1.2-GFP (macroH2A1.2). Images
were taken with respective channels for DAPI (blue) and GFP (green). C and D, MTT assay in HepG2 (C) and Huh-7 (D) cells after 72 h with decitabine (decit, 12 mM) or
guadecitabine (SGI-110, 1 or 5 mM) incubation. Percentage growth is with untreated GFP control cells. All data were expressed as mean § standard error of mean (SEM)
of 4 independent experiments.  P < 0.001 vs. untreated GFP-expressing cells. # P < 0.01 and ## P < 0.001 vs. decitabine-treated GFP-expressing cells.
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a distinctive feature of poor-prognosis cancers.18 We thus inter-
rogated our previously generated RNA-Seq data of GFP, mac-
roH2A1.1-GFP, or macroH2A1.2-GFP HepG2 cells for CDA
expression, uncovering signiﬁcantly higher mRNA expression
of the enzyme in macro histone-overexpressing cells (Fig. 7A).3
We validated these changes in mRNA expression levels at the
protein level by immunoblotting analysis, which showed consis-
tent increase in CDA in decitabine-resistant macroH2A1-trans-
genic HepG2 cells compared to GFP control cells (Fig. 7B). Our
data suggest increased pharmacological responsiveness of HCC
cells to guadecitabine compared to decitabine, despite CDA
upregulation mediated by macroH2A1, which in turn is highly
expressed in HCC.3,7
Guadecitabine-dependent promoter demethylation
of tumor suppressor genes in HCC cells
Some of the epigenetic hallmarks of HCC are hypermethy-
lation of TSGs and hypomethylation of unique genes and
repetitive sequences, such as LINE-1, leading to global
DNA hypomethylation. Our previous global analysis of
DNA methylation using the Luminometric Methylation
Assay (LUMA) showed similar genome-wide methylation
levels in HepG2 and Huh-7 cells.3 Basal-state analysis of 22
human tumor suppressor genes involved in HCC
highlighted a similar trend of promoter methylation
between the 2 cell lines for 16 tumor suppressor genes,
while only 6 genes exhibited main differences in the levels
of their hypermethylated promoters (Supplemental Table 1).
MacroH2A1-transgene overexpressing HepG2 and Huh-7
HCC cells were responsive to guadecitabine treatment
(Fig. 6), and macroH2A1 and DNA methylation synergized
in suppressing TSG genes expression.9 Therefore, we sought
to study DNA promoter hypermethylation from a subset of
genes identiﬁed in human HCC tissues that were demethy-
lated by guadecitabine (Fig. 4). To this purpose, we used
sets of primers previously validated for their speciﬁcity by
quantitative methylation-speciﬁc PCR (Table 1) to amplify
unmethylated or methylated CpG islands within the pro-
moters of CDKN2A, DLEC1, and RUNX3, and we measured
the unmethylated (U) vs. methylated (M) ratios in our
HepG2 and Huh-7 cell lines upon prolonged exposure to
guadecitabine (1 mM for 3 days). As expected, control GFP-
overexpressing HepG2 and Huh-7 cells displayed demethy-
lated levels of CDKN2A, DLEC1, and RUNX3 after treat-
ment with guadecitabine (Fig. 8A and B). At the basal state,
TSG promoter methylation levels did not differ in mac-
roH2A1.1- and macroH2A1.2-overexpressing HCC cells
(Fig. 8A and B). However, after treatment with guadecita-
bine, demethylation events on TSG promoters in mac-
roH2A1 histones-overexpressing HCC cells were not
occurring to the same extent or were discordant from con-
trol cells, with the exception of CDKN2A and DLEC1 in
macroH2A1.2-overexpressing Huh-7 cells (Fig. 8A and B).
These data suggest that macroH2A1 histone upregulation
(as observed in HCC tissue, Fig. 5) directly or indirectly
interfere with guadecitabine-induced TSG promoter
demethylation.
Figure 7. Cytidine deaminase (CDA) levels in HepG2 overexpressing GFP (control), macroH2A1.1 or macroH2A1.2 histone variants. A. CDA mRNA levels were averaged
from 3 independent RNA-Seq experiments. B. CDA protein levels were analyzed by immunoblotting. b¡actin was used as internal loading control. Representative images
of 3 independent experiments are shown.  P < 0.001 vs. GFP-expressing cells.
Table 1. qPCR primers for methylated/unmethylated gene promoters. Mf= meth-
ylated forward; Mr= methylated reverse; Uf: unmethylated forward; Ur: unmethy-
lated reverse.
Runx3 - Mf CGTCGGGTTAGCGAGGTTTC
Runx3 - Mr GCCGCTACCGCGAAAAACGA
Runx3 - Uf GTGGGTGGTTGTTGGGTTAGT
Runx3 - Ur TCCTCAACCACCACTACCACA
from Mori T et al. Liver
International 2005: 25:
380–388.
DLEC1 - Mf
GTTTCGTAGTTCGGTTTCGTC
DLEC1 - Mr CGAAATATCTTAAATACGCAACG
DLEC1 - Uf TAGTTTTGTAGTTTGGTTTTGTT
DLEC1 - Ur ACAAAATATCTTAAATACACAACA
from Qiu GH et al. J Hepatol
2008: 48(3): 433–441.
CDKN2A - Mf
TTATTAGAGGGTGGGGCGGATCGC
CDKN2A - Mr GACCCCGAACCGCGACCGTAA
CDKN2A - Uf TTATTAGAGGGTGGGGTGGATTGT
CDKN2A - Ur CAACCCCAAACCACAACCATAA
from Hinrichsen I et al. PLOS ONE 2014: 9(1): e84453.
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Discussion
The deregulation of epigenetic mechanisms, which maintain
heritable gene expression changes and chromatin organization,
is implicated in the development of HCC. Several independent
genome-wide methylation proﬁle studies demonstrated that
HCC tumors display differential DNA methylation patterns
compared to the adjacent normal liver tissues; these features
have been proposed as tools for early diagnosis and prognosis of
HCC.3-5,26 Mechanistic studies involved chromatin remodeling
complexes and microRNAs in HCC development, while the role
of histone post-translational modiﬁcations, such as acetylation
and methylation, is limited to correlative studies with clinical
features of HCC. Most histones are synthesized at S phase for
rapid deposition behind replication forks: the replacement of
histones deposited during S phase by variants that can be
deposited independently of replication provide one of the most
fundamental level of chromatin differentiation.27 Our laboratory
demonstrated for the ﬁrst time that the largest histone variant,
namely macroH2A1, and its 2 splicing isoforms, macroH2A1.1
and macroH2A1.2, marks the progression of liver diseases from
NAFLD to HCC.3,6,7,28 While it has been shown that mac-
roH2A1.1 acts as a tumor suppressor in many cancer types, the
role of macroH2A1.2 is context-dependent.8 Speciﬁcally, in
HCC, macroH2A1 isoforms display similar and overlapping
oncogenic roles, and there is a lack of linearity in macroH2A1
pre-mRNA splicing processes identiﬁed in malignant vs. adja-
cent normal parenchyma.3,7,29 MacroH2A1 confers resistance to
the anti-HCC activity of decitabine (5-Aza-20-deoxycytidine),
an epigenetic modiﬁer that demethylates DNA and exerts tumor
suppressor gene activation by remodeling.10-12 MacroH2A1
overexpression in HCC cells leads to the hypersecretion of IL-8,
Figure 8. Quantitative methylation-speciﬁc PCR of CpG islands of TSG (CDKN2A, DLEC1, and RUNX3) promoters in HCC cells. HepG2 cells (A) and Huh-7 cells (B) stably
overexpressing GFP, macroH2A1.1-GFP, or macroH2A1.2-GFP were treated with 1 mM guadecitabine (SGI-110) for 72 h prior to DNA extraction, bisulﬁte conversion, and
processing for qPCR. Primer sequences are shown in Table 1. Results are expressed as fold changes of controls (GFP) and as ratios between unmethylated (U) and methyl-
ated (M) DNA levels. All data were expressed as mean § SEM of four independent experiments. P < 0.05 vs. untreated GFP-expressing cells.
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which allows cancer cells to bypass the stall in proliferation/
senescence induced by decitabine.3 In the clinic, decitabine is
successfully used for the treatment of myelodysplastic syn-
dromes and for acute myeloid leukemia (AML), rather than for
less proliferative diseases and for solid tumors, such as HCC,
due to its short half-life in the blood: only 15 to 25 min, due to
rapid inactivation by liver and gut CDA. For this reason, guade-
citabine (SGI-110), a novel hypomethylating dinucleotide of
decitabine and deoxyguanosine resistant to degradation by
CDA, has been devised. In ongoing trials, guadecitabine was
given on 5 consecutive days in a 28-day cycle, showing safety
and tolerability in patients.16,30 Recent studies showed that gua-
decitabine is effective in reducing tumor burdening by reprog-
raming the epigenome as a single agent and in combination with
other chemotherapeutic agents in immunocompromised mice
xenografts and in cell models of lung cancer,31 ovarian can-
cer,17,26 and HCC.13 In the current study, we conﬁrmed the
inhibitor effect of guadecitabine on HCC cancer growth in
immunocompromised mice: smaller tumors developed in the
presence of guadecitabine and were characterized by extensive
demethylation of the promoters of tumor suppressor genes
DAB2IP, DLEC1, GSTP1, RASSF1, RUNX3, and SOCS1. We also
provided new evidence that the decrease in tumor burden might
be due to a decrease in vascularization, as indicated by decreased
isolectin B4 staining in tumor explants. Neo-angiogenesis is a
key process in tumorigenesis; the methylated genomic targets of
guadecitabine involved in angiogenesis and vascular sprouting
remain to be elucidated. Furthermore, HepG2 and HuH-7 HCC
cells overexpressing macroH2A1 isoforms that were refractory
to decitabine treatment in vitro, displayed instead growth inhibi-
tion upon guadecitabine treatment, even at lower doses (1 and
5 mM) compared to decitabine (12 mM). We explain this dis-
crepancy between decitabine and guadecitabine effects by the
macroH2A1-dependent upregulation of CDA that emerged
from RNA-Seq data and conﬁrmed at the protein level in
HepG2 cells overexpressing these histone variants.
HCC is a typical age-associated disease that develops over
decades with strong risk factors coming from viral infections
and alcohol consumption, and a common hallmark of a
ﬁbrotic/cirrhotic tissue background regardless of the etiol-
ogy.2,23,32 Here, we evaluated the efﬁcacy of guadecitabine in
blocking the progression of ﬁbrosis in the STAM mouse, an
established model of NASH, where ﬁbrosis and inﬂammation
are triggered by an initial injection of streptozocin in new born
animals (which damage pancreatic b cells), followed by high fat
diet feeding until 10 weeks of age. Despite using a dose (2 mg/
kg) that correlates with the demethylation of LINE-1 elements
in mice blood and liver (read-outs of its demethylating efﬁ-
cacy), guadecitabine treatment had no effect on liver ﬁbrosis
and proliferative foci formation in this NASH mouse model.
We did not observe amelioration of transaminases levels, trigly-
cerides, or in the appearance of histological markers of the dis-
ease, aSMA and glutamine synthetase, in the livers of control
vehicle-injected and guadecitabine-injected mice. Liver ﬁbrosis
is orchestrated by the activation of hepatic stellate cells (HSC),
responsible for extracellular matrix deposition.33 In contrast to
HCC, to date, genome-wide studies of changes in DNA methyl-
ation during HSC activation have not been reported and the
prominent ones using human liver biopsies were to some extent
conceptually and methodologically criticized;34-37 therefore,
changes in DNA methylation proﬁles might not play a role in
hepatic ﬁbrogenesis, a risk factor for HCC. However other
studies showed that decitabine inhibit HSC activation.37 Inter-
estingly, the livers of STAM mice exhibited an increase in
DNMT1, which has been consistently detected in human liver
ﬁbrosis or upon HCV infection,38,39 compared to healthy mice
livers. Administration of guadecitabine restored physiological
DNMT1 levels; the precise role of DNMT1 in the transition
from NASH to HCC and whether guadecitabine could inﬂu-
ence the progression of liver disease remain unknown. An alter-
native explanation for the lack of guadecitabine effects on liver
ﬁbrosis in vivo is related to the high levels of CDA expression
in this organ, which provides a hostile place for the stability of
the drug and its effects on HSC and cancer cells. This mecha-
nism of resistance could be reversed in mice, without toxicity,
by combining decitabine with an inhibitor of CDA.19 Combina-
tion of new DNA hypomethylating agents and CDA inhibitors
is a new type of strategy now employed in ongoing clinical trials
for several malignancies.20 In fact, early studies using the CDA
inhibitor tetrahydrouridine (THU) have shown proof of princi-
ple for combinatorial approach together with decitabine
although its instability has prevented further development as a
therapeutic.40 Ongoing efforts to develop ﬂuorinated deriva-
tives of THU, which are resistant to degradation and can be co-
administered with guadecitabine, will pave the way for more
potent hypomethylation therapies against liver diseases and
HCC. Regardless of clinical efﬁcacy, DNA methylation markers
can be used as prognostic biomarkers for HCC. Our methyla-
tion analysis showed differences in 10 genes between healthy
liver tissue and malignant human HCC tissue: CDKN1A,
CDKN2A, DLEC1, E2F1, GSTP1, OPCML, E2F1, RASSF1,
RUNX3 and SOCS1. It would be interesting to follow up on
these 10 differentially methylated markers in liver samples
from a larger cohort of patients to screen for therapy respond-
ers/non-responders, and to study the correlation of these 9
markers with response/relapse. MacroH2A1 and DNA methyl-
ation synergize in suppressing TSG p16 expression9; therefore,
we analyzed DNA promoter methylation levels from an arbi-
trary subset of 3 among these 10 genes identiﬁed in human
HCC tissues that were demethylated by guadecitabine
(CDKN2A, DLEC1, and RUNX3) in HCC cell lines, HepG2,
and Huh-7 overexpressing histone variant macroH2A1 iso-
forms. At the basal level, control HepG2 and Huh-7 cell lines
show similar HCC gene promoter methylation signature, with
major differences observable only in 6 of the 22 genes analyzed
(Supplemental Table 1), which can be possibly linked to the
considerable differences in the genetic make up (p53 expres-
sion) and differentiation/proliferative behavior of these 2 cell
lines.41 In contrast to control cells, cells overexpressing mac-
roH2A1 isoforms responded unevenly and, to a lesser extent, to
guadecitabine in terms of TSG promoter demethylation, despite
the fact that they were more responsive to guadecitabine com-
pared to decitabine for inhibition of proliferation. This might
be explained by i) wider guadecitabine-dependent DNA hypo-
methylation effects beyond the TSGs we analyzed, resulting in
pleiotropic tumor suppression, overcoming macroH2A1 incor-
poration into chromatin, which might affect local demethyla-
tion on speciﬁc TSGs; and/or ii) intrinsic discrepancies in TSG
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methylation patterns between HCC cell lines and human biop-
sies. Chromatin co-immunoprecipitation studies using anti-
bodies against macroH2A1 and DNA methylation marker 5-
methylcytosine will help untangle these epigenetic interactions
during HCC development. In summary, our data demonstrate
that guadecitabine is effective in counteracting growth and vas-
cularization in HCC xenografts and in HCC cells refractory to
decitabine, while its efﬁcacy as a single agent or in combination
in pre-clinical models of ﬁbrosis/cirrhosis requires further
investigation. Effective hypomethylating agents will hopefully
provide HCC patients with more potent therapeutic strategies
in the future.
Materials and methods
Xenograft models
Female athymic nude mice (strain Hsd: Athymic Nude-
Foxn1nu) were purchased from Harlan Laboratories (Horst,
Netherlands) and allowed to acclimatize for a week at the Ani-
mal Facility of Tallinn University of Technology. The study
was conducted in accordance with European Directive 2010/
63/EU and National Animal Welfare legislation; the experi-
mental protocol was approved by the ethical committee of
Estonian Ministry of Agriculture (now Ministry of Rural
Affairs). Animals were housed under 12 h light/dark cycles in a
humidity and temperature-controlled room (temperature 22 §
1C and humidity 50 § 10%). Mice were housed at 6–8 mice
per cage with ad libitum access to clean water and food pellets
(R35, Lactamin, Sweden) and their health was monitored daily.
Six week-old mice were implanted subcutaneously (s.c.) with
human hepatocellular carcinoma HepG2 cells stably expressing
GFP.3 For this, stable HepG2 cells were cultured to 70–80%
conﬂuency, harvested and suspended in complete media mixed
1:1 with Matrigel Matrix (Cat# 356234, Becton Dickinson, Bed-
ford, MA). The suspension containing 7.5 £ 106 cells (150 ml)
was injected s.c. into the right ﬂank of each mouse. Ten days
later, mice were randomly assigned into the test group receiving
guadecitabine treatment (n D 14), and the control group
receiving vehicle (n D 14). For this, guadecitabine (provided by
Astex Pharmaceuticals) reconstituted in its diluent buffer (con-
taining 65% Propylene Glycol, 25% Glycerin, 10% Dehydrated
Ethanol, 200 proof) was freshly diluted 100£ in PBS and
injected s.c. into the neck skin fold at 2 mg/kg and at a volume
10 ml/kg body weight on 5 consecutive days. About 15% of the
guadecitabine-treated animals exhibited signs of weakness and
10% weight loss. Tumor sizes were measured 2–3 times per
week with a digital caliper and the tumor volume was calcu-
lated using the ellipsoid formula: length £ width 2 £ 0.5. Mice
were euthanized 5 weeks after xenograft implantation, and
tumors were dissected, weighed, and processed for further anal-
ysis. Unpaired Student’s t-test was performed for data analysis
and P < 0.05 was considered signiﬁcant.
Non-alcoholic steatohepatitis mouse model
The non-alcohonlic steatohepaptitis (NASH) model, a STAM
mouse, was generated as previously described24 and outsourced
at SMC Laboratories, Tokyo, Japan. Brieﬂy, C57BL/6J mice
were purchased from Charles River (Kanagawa, Japan) at 15 d
post pregnancy. On the second day after birth, male mice were
subjected to a single subcutaneous injection of 200mg strepto-
zotocin (Sigma, MO, USA). Four weeks after injection, mice
were fed a high fat diet (HFD32, CLEA JAPAN, Tokyo, Japan)
ad libitum until sacriﬁce at 12 weeks. Two experimental groups
were considered, a control group (n D 9) and a group injected
s.c. with guadecitabine (2 mg/kg, guadecitabine, Astex Pharma-
ceuticals) (n D 9) at week 8 for 3 consecutive days. Mice were
sacriﬁced at week 10. Blood glucose and serum insulin levels
were measured by a blood glucose meter (Glutest Ace, Sanwa
Chemical, Nagoya, Japan) and Morinaga Ultra Sensitive
Mouse/Rat Insulin ELISA Kit (Morinaga Institute of Biological
Science, Yokohama, Japan), respectively. At 8 weeks, animal
experiments were conducted according to protocols approved
by the Animal Research Committee at Research Institute,
National Center for Global Health and Medicine. Mice were
maintained according to National Institutes of Health guide-
lines for care and use of laboratory animals.
LINE-1 methylation assay
Genomic DNAs were extracted from whole blood of 8 balb/c
mice 8 d post s.c. injection with 2 mg/kg guadecitabine, using
the Illustra blood genomic Prep Mini Spin Kit (GE Healthcare,
UK) according to the manufacturer’s protocol and stored at
¡20C. DNA extracts were prepared from human HCC cell
lines, human tumor and normal liver tissues, and from mice
livers using the DNA Mini Kit (Qiagen). DNA concentrations
were measured by NanoDrop analysis before the direct bisulﬁte
conversion procedure using the EpiTect Fast DNA Bisulﬁte Kit
(Qiagen), followed by a Mouse or a Human LINE-1 PCR reac-
tion (EpigenDX). Methylation levels were analyzed on a Pyro-
MarkQ24 instrument including methylation control DNAs to
validate each sample set. The degree of methylation was
expressed as percentage of methylated cytosines over the sum
of methylated and unmethylated cytosines.
Tumor samples and methylation arrays
For human tumors, DNA was obtained from HuPrime
Patient-Derived Xenograft (PDX) Sorafenib-resistant HCC tis-
sues (CrownBio International R&D Center, Taicang, P.R.
China). DNA was also extracted from normal liver tissue
(Donor HH180 lot 99; BD Bioscience, UK). For mice tumors,
DNA was extracted from tumors of guadecitabine-injected and
PBS-injected mice using the DNA Mini Kit (Qiagen). A DNA
methylation signature for 22 genes was determined using the
human EpiTect DNA Methylation PCR Array platform for
liver cancer (Qiagen) on a ViiA-7 RT-PCR instrument
(Applied Biosciences).
Immunohistochemistry on steatotic, cirrhotic, and HCC
human biopsies
Liver specimens were obtained from patients undergoing clini-
cally indicated hepatic biopsies, with appropriate institutional
(University of Palermo) ethical approval and patient consent
and in accordance with the Code of Ethics of the World
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Medical Association (Declaration of Helsinki).3,7 Liver sections
in parafﬁn-embedded (4-mm thick, 10 per condition) were
stained with hematoxylin and eosin (H&E) and Masson’s tri-
chrome for histologic evaluation, as described previously.3,7
Diagnostic classiﬁcation of NAFLD and ﬁbrosis/cirrhosis was
performed using a semiquantitative scoring system that
grouped histologic features into broad categories (steatosis,
hepatocellular injury, portal inﬂammation, ﬁbrosis, and miscel-
laneous features).
Histology, immunohistochemistry, and
immunoﬂuorescence in mice
Tumor samples from xenograft models were formalin-ﬁxed,
parafﬁn-embedded and processed for H&E staining, using
standard procedures. Isolectin IB4 protein was detected using
Isolectin GS-IB4 Alexa ﬂuor 488 conjugate antibody (Thermo-
ﬁsher Scientiﬁc, catalog number I21411) and incubated over-
night at 4C. Samples were then washed with PBS and nuclei
were stained with DAPI for 5 min. Samples were ﬁnally
mounted and conserved at ¡20C before images were acquired
using an optical microscope (Leica). Liver samples from the
STAM model were ﬁxed in 4% buffered paraformaldehyde,
embedded in parafﬁn, stained with H&E or Masson’s tri-
chrome, and examined by light microscopy, as previously
described.24,25 Alternatively, samples were processed for immu-
nohistochemical staining with antibodies against aSMA or glu-
tamine synthetase.24,25
Constructs, cell cultures, and proliferation assay
Stable expression of macroH2A1 isoforms tagged with GFP in
HepG2 and Huh-7 cells was achieved by lentiviral transduction.
cDNAs encoding macroH2A1 isoforms were placed under the
control of a strong constitutive EF1a-promoter in the HIV1-
based self-inactivating lentiviral vector. The vectors were modi-
ﬁed to allow expression of macroH2A isoforms as N-terminal
fusions with a monomeric ﬂuorescent protein mTagGFP, and
via the ECMV internal ribosomal entry site element of the
puromycin resistance gene. All constructs were veriﬁed by
sequencing. Viral preparations were produced by transient
transfection in HEK293T cells, and concentrated 100-fold by
low-speed centrifugation (6000 g for 16 h). HepG2 and Huh-7
cells were transduced with virus at MOI>10 for 24 h in the
presence of 4 mg/mL Polybrene. Stably transduced cell popula-
tions were established and used in subsequent experiments
without clonal selection. To generate appropriate controls, cells
were also stably transduced with the empty vector (expressing
only mTagGFP) and maintained in culture conditions similar
to macroH2A1-expressing cells. For all experiments, cells were
treated for 72 h with 5 or 10 mM of guadecitabine (SGI-110,
Astex Pharmaceuticals). Cell proliferation was assessed by
MTT assay, as previously described.42,43
Methylation-speciﬁc PCR
DNA extracted from HepG2 and Huh-7 cells expressing GFP,
macroH2A1.1-GFP or macroH2A1.2-GFP, was subjected to
bisulphite treatment and DNA puriﬁcation using the Epitect
Bisulphite kit (Qiagen Sci, MD, USA) according to manufac-
turer instructions. Bisulﬁte-modiﬁed DNA was used as tem-
plate for ﬂuorescence-based real-time PCR using a relative
quantiﬁcation method.44 Primers were designed to speciﬁcally
amplify the bisulphite-modiﬁed region of the genes of interest
containing the putative methylated CpGs. Primer sequences for
the 5 genes whose promoters were examined are provided in
Table 1. Ampliﬁcation reactions were carried out in triplicate
in a volume of 20 mL containing 50 ng bisulphite-modiﬁed
DNA, 600 nM forward and reverse primers, and SYBR green
mix (Qiagen Sci, MD, USA). PCR conditions were as follows:
one step at 95C for 3 min, 40 cycles at 95C for 15 s, and 60C
to 62C for 1 min. PCR reactions were performed in 96-well
plates on a ABI PRISM 7700 Sequence detection system
(Applied Biosystems, Carlsbad, CA) and were analyzed by SDS
2.1.1 software (Applied Biosystems, Foster City, CA).
RNA-Seq
For RNA-Seq, total RNA was extracted from macroH2A1.1-
GFP, macroH2A1.2-GFP, and GFP transgenic HepG2 cell lines
with TRIzol Reagent (Invitrogen). Indexed libraries were pre-
pared from 2 mg/ea puriﬁed RNA with the TruSeq Total
Stranded RNA Sample Prep Kit (Illumina), according to the
manufacturer’s instructions. Libraries were quantiﬁed using the
Agilent 2100 Bioanalyzer (Agilent Technologies) and pooled so
that each index-tagged sample was present in equimolar
amounts; the ﬁnal concentration of the pooled samples was 2
nmol/L. Pooled samples were then subjected to cluster genera-
tion and sequencing using an Illumina HiSeq 2500 System
(Illumina, Genomix4Life, Baronissi, Salerno, Italy) in a 2 £ 100
paired-end format at a ﬁnal concentration of 8 pmol/L.
Western blot
Protein extracts from macroH2A1.1-GFP, macroH2A1.2-GFP,
and GFP transgenic HepG2 and Huh-7 cells were isolated and
processed for immunoblotting as described previously.3,45 Pri-
mary antibody against CDA and DNA methyltransferases
(DNMT1, DNMT3a, and DNMT3b) were obtained from Activ
Motif and Cell Signaling, respectively. Antibody against b-actin
(Santa Cruz Biotechnology) was used as total protein loading
control for normalization.
Statistical analyses
Results were expressed as mean § standard error of the mean
(SEM). Comparisons between means were made by appropriate
Student t tests. Differences of proportions were assessed by
one-tailed x2 tests. Differences were considered as signiﬁcant
when P < 0.05.
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